Abstract
Cardiac PET perfusion and viability imaging has gained considerable acceptance in the cardiology and imaging communities due to the efficiency of testing procedures and excellent image quality. These attributes are in part due to the radiopharmaceuticals available for Cardiac PET. Most PET radiopharmaceuticals have radioisotopes with shorter half-lives than those of SPECT tracers. This enables patient imaging protocols to provide rapid repeat testing such as rest followed quickly by stress imaging (25–40 min). The short half-lives can also reduce radiation exposure for some PET agents. However the very short half-life for some PET perfusion agents means that exercise imaging is generally not possible. This may change with availability of newer slightly longer half-life PET tracers.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fowler JS, Wolf AP. Positron emission tomography and autoradiography principles and applications for the brain and heart. In: Phelps M, Mazziotta J, editors. Clinical cardiology. New York: Raven Press; 1986. p. 391–450.
Biersack H, Freeman L. Clinical nuclear medicine. Berlin/Heidelberg: Springer; 2007.
IAEA. Cyclotron produced radionuclides: guidelines for setting up a facility. Vienna: IAEA; 2009. p. 213.
Herzog BA, Husmann L, Valenta I, Gaemperli O, Siegrist PT, Tay FM, Burkhard N, Wyss CA, Kaufmann PA. Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. J Am Coll Cardiol. 2009;54:150–6.
Ziadi MC, Beanlands R, DeKemp R, Renaud J, Tee RE, Guo A, Williams K, Chow B, Ruddy TD, Hessian R, Garrard L, Davies RA, Etele J. Impaired mfr measured using Rb-82 predicts outcomes in patients with suspected ischemia. Circulation. 2009;120:S320.
Love WD, Burch GE. Influence of the rate of coronary plasma flow on the extraction of Rb86 from coronary blood. Circ Res. 1959;7:24–30.
Lortie M, Beanlands RS, Yoshinaga K, Klein R, Dasilva JN, DeKemp RA. Quantification of myocardial blood flow with 82Rb dynamic pet imaging. Eur J Nucl Med Mol Imaging. 2007;34:1765–74.
El Fakhri G, Kardan A, Sitek A, Dorbala S, Abi-Hatem N, Lahoud Y, Fischman A, Coughlan M, Yasuda T, Di Carli MF. Reproducibility and accuracy of quantitative myocardial blood flow assessment with (82)Rb pet: comparison with (13)N-ammonia pet. J Nucl Med. 2009;50:1062–71.
Klein R, Renaud JM, Ziadi MC, Thorn SL, Adler A, Beanlands RS, deKemp RA. Intra- and inter-operator repeatability of myocardial blood flow and myocardial flow reserve measurements using rubidium-82 pet and a highly automated analysis program. J Nucl Cardiol. 2010;17:600–16.
Di Carli MF, Hachamovitch R. New technology for noninvasive evaluation of coronary artery disease. Circulation. 2007;115:1464–80.
Sampson UK, Dorbala S, Limaye A, Kwong R, Di Carli MF. Diagnostic accuracy of rubidium-82 myocardial perfusion imaging with hybrid positron emission tomography/computed tomography in the detection of coronary artery disease. J Am Coll Cardiol. 2007;49:1052–8.
Schelbert H. Quantifying myocardial perfusion for the assessment of preclinical cad. In: Cardiac PET and PET/CT. New York: Springer; 2007. p. 166–77.
Takala T, Nuutila P, Katoh C, Luotolahti M, Bergman J, Maki M, Oikonen V, Ruotsalainen U, Gronroos T, Haaparanta M, Kapanen J, Knuuti J. Myocardial blood flow, oxygen consumption and fatty acid uptake in endurance athletes during insulin stimulation. Am J Physiol. 1999;4(Pt 1):E585–90.
Hickey KT, Sciacca RR, Bokhari S, Rodriguez O, Chou RL, Faber TL, Cooke CD, Garcia EV, Nichols K, Bergmann SR. Assessment of cardiac wall motion and ejection fraction with gated pet using N-13 ammonia. Clin Nucl Med. 2004;29:243–8.
Maddahi J, Czernin J, Lazewatsky J, Huang SC, Dahlbom M, Schelbert H, Sparks R, Ehlgen A, Crane P, Zhu Q, Devine M, Phelps M. Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest. J Nucl Med. 2011;52:1490–8.
Dilsizian V, Pohost GM, editors. Cardiac PET, CT and MR. Oxford: Wiley-Blackwell; 2010. p. 120–2.
Fuller RW, Snoddy HD, Perry KW, Bernstein JR, Murphy PJ. Formation of alpha-methylnorepinephrine as a metabolite of metaraminol in guinea pigs. Biochem Pharmacol. 1981;30:2831–6.
Matsunari I, Aoki H, Nomura Y, Takeda N, Chen WP, Taki J, Nakajima K, Nekolla SG, Kinuya S, Kajinami K. Iodine-123 metaiodobenzylguanidine imaging and carbon-11 hydroxyephedrine positron emission tomography compared in patients with left ventricular dysfunction. Circ Cardiovasc Imaging. 2010;3:595–603.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag London
About this chapter
Cite this chapter
DaSilva, J.N., Valadiva, A.C., Mylonas, I., Hadizad, T., deKemp, R.A., Beanlands, R.S.B. (2013). PET Radiopharmaceuticals. In: Heller, G., Hendel, R. (eds) Handbook of Nuclear Cardiology. Springer, London. https://doi.org/10.1007/978-1-4471-2945-5_13
Download citation
DOI: https://doi.org/10.1007/978-1-4471-2945-5_13
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-2944-8
Online ISBN: 978-1-4471-2945-5
eBook Packages: MedicineMedicine (R0)